Valuation of an Early Stage Company
Fox Rothschild LLP partners Gerard P. Norton, Jeffrey Nicholas, and Valli Baldassano will speak at the Biotech 2007 symposium. The symposium will be held on October 8-9, 2007, at the Loews Hotel in Philadelphia, PA.
Norton will serve as a moderator for "Funding Early-Stage Bioscience Companies: Do You Have What It Takes?" The group will discuss key issues and challenges with both traditional and creative sources of pre-seed, seed, Series A, and Series B funding.
Nicholas will moderate a session entitled, "Valuation of an Early Stage Company," which will explore aspects of early-stage company valuation and the range of potential exits available to entrepreneurs.
Baldassano will be a panelist for "Preparing for Launch: An Overview of Essential Legal and Regulatory Requirements for Marketing and Selling Prescription Drugs in the U.S." The group will discuss best practices for setting up an effective compliance program to ensure that the marketing and sales of prescription drugs abide by all federal and state laws.
All three partners belong to Fox Rothschild's Life Sciences Practice Area, a group of experienced lawyers providing counsel to life science companies at every stage across the spectrum of intellectual property, financing, and corporate compliance issues.
Biotech 2007, which is hosted jointly by BioNJ and Pennsylvania Bio, focuses on the biosciences industry in the Mid-Atlantic region. The symposium is designed to advance the growth and development of the bioscience industry and facilitate networking opportunities among emerging companies, researchers, and large pharmaceutical companies.